These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16859132)

  • 1. [Effect of lamivudine treatment on the quality of life of chronic hepatitis B].
    Yi LX; Yang X; Wang XW
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):396-9. PubMed ID: 16859132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
    Ramezani A; Velayati AA; Roshan MR; Gachkar L; Banifazl M; Keyvani H; Aghakhani A
    Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC; Liu CJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
    Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
    Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with non-alcoholic fatty liver disease.
    Dan AA; Kallman JB; Wheeler A; Younoszai Z; Collantes R; Bondini S; Gerber L; Younossi ZM
    Aliment Pharmacol Ther; 2007 Sep; 26(6):815-20. PubMed ID: 17767465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
    Kennedy PT; Phillips N; Chandrasekhar J; Jacobs R; Jacobs M; Dusheiko G
    Liver Int; 2008 May; 28(5):699-704. PubMed ID: 18433396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
    J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
    Yeh CT; Hsu CW; Chen YC; Liaw YF
    J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of quality of life in chronic hepatitis C: effect of treatment].
    Desmorat H; Combis JM; Pradat P
    Gastroenterol Clin Biol; 2003 Dec; 27(12):1084-90. PubMed ID: 14770108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
    Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
    Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.